Sigilon Therapeutics is a biotechnology company developing immunotherapies for the treatment of chronic diseases that is headquartered in Cambridge, Massachusetts and was founded in 2015 by Daniel Anderson, Robert Langer, Jose Oberholzher, Arturo Vegas, and Omid Veiseh.
The company looks to engineer human cells that are capable of restoring to a normal physiology after a range of diseases, and doing so without generating fibrosis, or immune rejection. They operate in fields of biotechnology, hemophilia, diabetes, lysosomal storage disorders, bio-compatible materials, and chronic disease solutions.
Sigilon Therapeutics has the goal of creating what they refer to as Shielded Living Therapeutics, which are engineered cells that provide a functional cure for chronic diseases. They have completed trials of their therapeutics in animals, and predict that should they succeed in human cases, these solutions will help generate the natural biomolecules a patient requires to maintain therapeutic protein replacement over long-term periods.
Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
Eli Lilly and Company
October 18, 2018
Sigilon Therapeutics and MIT Announce Research Collaboration to Advance Programmable Living Therapeutics for Serious Chronic Diseases
Sigilon Therapeutics Expands Intellectual Property Portfolio with New Patent Issued